Background-Heart failure with preserved ejection fraction is 1 consequence of hypertension and is caused by impaired cardiac diastolic relaxation. Nitric oxide (NO) is a known modulator of cardiac relaxation. Hypertension can lead to a reduction in vascular NO, in part because NO synthase (NOS) becomes uncoupled when oxidative depletion of its cofactor tetrahydrobiopterin (BH 4 ) occurs. Similar events may occur in the heart that lead to uncoupled NOS and diastolic dysfunction. Methods and Results-In a hypertensive mouse model, diastolic dysfunction was accompanied by cardiac oxidation, a reduction in cardiac BH 4 , and uncoupled NOS. Compared with sham-operated animals, male mice with unilateral nephrectomy, with subcutaneous implantation of a controlled-release deoxycorticosterone acetate pellet, and given 1% saline to drink were mildly hypertensive and had diastolic dysfunction in the absence of systolic dysfunction or cardiac hypertrophy. The hypertensive mouse hearts showed increased oxidized biopterins, NOS-dependent superoxide production, reduced NO production, and dephosphorylated phospholamban. Feeding hypertensive mice BH 4 (5 mg/d), but not treating with hydralazine or tetrahydroneopterin, improved cardiac BH 4 stores, phosphorylated phospholamban levels, and diastolic dysfunction. Isolated cardiomyocyte experiments revealed impaired relaxation that was normalized with short-term BH 4 treatment. Targeted cardiac overexpression of angiotensin-converting enzyme also resulted in cardiac oxidation, NOS uncoupling, and diastolic dysfunction in the absence of hypertension.
H eart failure with preserved ejection fraction as a result of diastolic dysfunction accounts for significant mortality and healthcare expenditures, especially among hypertensive individuals. 1, 2 The incidence of this type of heart failure is increasing. 1 
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There are no specific treatments for diastolic dysfunction, partly because of a relative lack of a mechanistic understanding of this disorder. 3 A strong epidemiological association exists between hypertension and diastolic dysfunction. 2, 4, 5 In the vasculature, hypertension and activation of the renin-angiotensin system lead to reduced vascular nitric oxide (NO), in part because NO synthase (NOS) becomes uncoupled when oxidative depletion of its cofactor tetrahydrobiopterin (BH 4 ) occurs, leading to production of superoxide (O 2 ⅐Ϫ ) instead of NO. 6 NO and NOS have recently been identified as having a role in the modulation of cardiac relaxation. 7 Therefore, we hypothesized that hypertension and/or activation of the renin-angiotensin system in the absence of an increase in blood pressure may lead to NOS uncoupling in the heart and to diastolic dysfunction.
Methods
All of the experiments were approved by the appropriate institutional animal care and use committees.
Hypertensive Mouse Model
We used a mouse model of hypertension to mimic the most common human risk factor for diastolic dysfunction (see the online-only Data Supplement). 2, 4, 5, 8 We have shown that this model leads to vascular oxidative stress, BH 4 depletion, and NOS uncoupling. 6 A subset of hypertensive mice were randomly selected on postoperative day 1 to receive 5 mg/d of either BH 4 (AXXORA, San Diego, CA) or tetrahydroneopterin (H 4 N), an enzymatically inactive analog of BH 4 with equivalent antioxidant properties (Schricks Laboratories, Jona, Switzerland). 9,10 A cohort of hypertensive deoxycorticosterone acetate (DOCA)-salt mice were randomized on postoperative day 11, a time when all DOCA-salt mice have evidence of diastolic dysfunction, to either 12 to 14 days of BH 4 feeding as described above or treatment with hydralazine (25 to 30 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 in 1% saline; Sigma-Aldrich, St. Louis, Mo).
Echocardiography was performed on a subset of mice 24 to 48 hours before terminal procedures. These procedures were done on postoperative day 14 for hypertensive DOCA-salt, BH 4 prevention, H 4 N, and control mice and on postoperative days 22 to 24 for mice in the BH 4 or hydralazine treatment groups (see the online-only Data Supplement).
Angiotensin-Converting Enzyme 1/8 Mouse Model
Male compound heterozygous angiotensin-converting enzyme (ACE) 1/8 mice and age-matched littermate controls were used to test whether cardiac oxidation could lead to diastolic dysfunction (see the online-only Data Supplement). 11 These mice have no hypertension, increased cardiac ACE, minimal extracardiac ACE expression, and preserved ejection fraction. 11
Noninvasive Assessment of Diastolic Dysfunction
Mice were studied by pulsed-wave tissue Doppler from the apical 4-chamber view. 12 Results correlated with invasive measures (see the online-only Data Supplement).
Invasive Assessment of Diastolic Dysfunction
The online-only Data Supplement provides details on the invasive assessment of diastolic dysfunction. 13
Cardiac Biopterin Content
Cardiac biopterins were measured as previously reported (see the online-only Data Supplement). 6,14 -16 
Measurement of Cardiac Superoxide
Cardiac O 2 ⅐Ϫ was measured with a dihydroethidium-based highperformance liquid chromatography assay as previously described. 17 Tissue either was kept in plain buffer or was treated with 1 mmol/L of the nonselective NOS inhibitor N -nitro-L-arginine methyl ester hydrochloride (L-NAME; Sigma) or 10 mol/L of the neuronal NOS (nNOS) inhibitor 7-nitroinidazole (7N; AXXORA, San Diego, Calif; see the online-only Data Supplement). 18 
NOS Activity and Expression
NOS activity was determined by measuring the conversion of [ 14 C]-labeled arginine to citrulline in myocardial homogenates (Calbiochem, San Diego, Calif). nNOS and endothelial NOS monomers were assayed with cold SDS-PAGE Western blot analysis under reducing conditions (see the online-only Data Supplement).
Phospholamban Expression
Frozen samples were homogenized in protease and phosphatase inhibitors (Sigma). SDS-PAGE was performed with a 15% acrylamide gel (see the online-only Data Supplement).
Myocyte Isolation and Cell Shortening
Cardiac ventricular myocytes were isolated and analyzed from the hearts of DOCA-salt mice 11 to 14 days postoperatively and of age-matched controls with a previously described protocol (see the online-only Data Supplement). 19, 20 
Histology
Heart tissue was stained with hematoxylin and eosin or Masson trichrome to determine myocyte cross-sectional diameter and interstitial fibrosis (see the online-only Data Supplement).
Statistical Analysis
Data are presented as meanϮSE unless otherwise specified. Comparisons between 2 groups were done with a 2-tailed Student t test. Multiple groups were compared by use of a 1-way ANOVA and a posthoc test (Student-Newman-Keuls or Bonferroni).
The authors had full access to and take full responsibility for the integrity of the data. All of the authors have read and agree to the manuscript as written.
Results

Hypertensive Mice Show Diastolic Dysfunction
Tail-cuff blood pressure measurements and echocardiograms were obtained on postoperative days 11 to 13 in DOCA-salt mice. Mean systolic blood pressure and heart rate were mildly elevated in conscious, acclimated hypertensive mice compared with age-matched controls (Table) .
Hypertensive mice had echocardiographic evidence of diastolic dysfunction 21, 22 (Figure 1 ). They had significant reduction in tissue mitral annulus early longitudinal (EЈ) velocities, ratio of tissue early to atria (EЈ/AЈ) velocities, and left ventricular (LV) inflow propagation velocity (Vp) compared with controls. The ratio of early diastolic filling velocity to the early diastolic mitral annulus velocity (E/EЈ) has been reported to have the highest correlation with invasive hemodynamic measures of diastolic dysfunction. 23 Hypertensive mice had a higher E/EЈ compared with controls, consistent with impaired relaxation. The mitral inflow velocities, E and A, were similar between groups. The normal E/A ratio in conjunction with abnormal tissue Doppler imaging and color M-mode measurements implied that this value was "pseudonormal," a pattern associated with advanced diastolic dysfunction. 24 The changes in relaxation parameters occurred in the absence of valvular regurgitation, LV wall motion abnormalities, or hypertrophy. Systolic function, including LV ejection fraction (percent), fractional shortening (percent), and septal annulus systolic velocity, was statistically indistinguishable between groups.
Invasive hemodynamic evaluation confirmed the echocardiographic findings ( Figure 2 ). As expected, LV end-systolic pressure and LV end-diastolic pressure were mildly elevated in hypertensive mice compared with controls (108Ϯ3 versus 95Ϯ2 mm Hg, Pϭ0.002; 7.2Ϯ0.7 versus 4.5Ϯ0.4 mm Hg, Pϭ0.004; Figures 2A through 2C) , respectively. Compared with controls, hypertensive mice had prolonged time constants for isovolumic relaxation calculated by 2 standard methods ( Weiss , 10.3Ϯ0.08 versus 8.1Ϯ0.03 ms, Pϭ0.02; Glantz , 5.9Ϯ0.02 versus 4.9Ϯ0.02 ms, Pϭ0.03; Figure 2D ). 25 The best fit for the end-diastolic pressure-volume relation (EDPVR) was described by the following linear function: pressure end diastole ϭEDPVRϫvolume end diastole ϩintercept (for both groups combined: median rϭ0.99; range, 0.91 to 0.99; Figures 2E and 2F ). Hypertensive DOCA-salt mice had a steeper EDPVR compared with controls (1.3Ϯ0.1 versus 0.67Ϯ0.1 mm Hg/L; Pϭ0.0004; Figure 2E ). Diastolic dysfunction did not appear to be the result of changes in myocardial systolic contractile properties. LV systolic function was preserved in hypertensive mice compared with controls as indicated by multiple invasive indexes, including the slope of the end-systolic pressure-volume relation (6.7Ϯ0.6 versus 5.3Ϯ0.5 mm Hg/L; PϭNS; Figure  2G ) and its volume axis intercept (Ϫ2.6Ϯ1.3 versus Ϫ1.6Ϯ2.1 mm Hg/L; PϭNS), LV ejection fraction (52Ϯ2.0% versus 45Ϯ1.1%; PϭNS), stroke volume (16.0Ϯ0.4 versus 14.4Ϯ0.4 L; Pϭ0.009), and peak rate of pressure rise (dP/dtmax; 10 690Ϯ459 versus 11 680Ϯ 470 mm Hg/s; PϭNS). Body weight was similar between the 2 groups (23.1Ϯ0.2 versus 23.3Ϯ0.2 g; PϭNS). These changes were unexplained by differences in heart rate (553Ϯ17 versus 547Ϯ10 bpm; PϭNS; Figure 2H ), and arterial elastance, a measure of vascular stiffness calculated by dividing the end-systolic pressure by stroke volume, was similar between hypertensive mice and controls (6.64Ϯ0.2 versus 6.67Ϯ0.3 mm Hg/L; PϭNS; Figure 2I ). 26 At a cellular level, LV tissue from mildly hypertensive mice did not show an increase in collagen staining with Masson trichrome ( Figure II of the online-only Data Supplement). Myocytes from DOCA-salt mice had similar cell diameters and length measurements compared with control cells (PϭNS ; Table) . Fractional shortening percent in isolated myocytes was similar between groups (PϭNS; Figure  III of the online-only Data Supplement).
In the DOCA-salt model, the changes in diastolic properties were dependent on the presence of mild hypertension. Mice implanted with a DOCA pellet in the absence of unilateral nephrectomy and salt supplementation had similar mean systolic blood pressure compared with controls (103.3Ϯ3 versus 99.5Ϯ3 mm Hg; PϭNS). There were no significant differences in ventricular relaxation in these mice compared with controls (EЈ, 5.0Ϯ0.6 versus 5.6Ϯ0.1 cm/s; Vp, 47.3Ϯ3.3 versus 50.8Ϯ1.9 cm/s; and E/EЈ, 18.2Ϯ1.9 versus 16.1Ϯ0.8; nϭ5 per group).
Diastolic Dysfunction Is Associated With Cardiac Oxidation
LV tissue obtained from hypertensive mice on postoperative day 14 showed a 2-fold increase in O 2 ⅐Ϫ as measured by 2-oxyethidium (2HO-ET) levels (0.09Ϯ0.01 versus 0.18Ϯ 0.02 mol ⅐ L Ϫ1 ⅐ mg Ϫ1 ; Pϭ0.02). Administering BH 4 to hypertensive mice on postoperative days 1 to 14 significantly blunted the increase in cardiac 2HO-ET compared with that observed in the untreated DOCA-salt group (0.12Ϯ0.01 versus 0.18Ϯ0.02 mol ⅐ L Ϫ1 ⅐ mg Ϫ1 ; Pϭ0.02; Figure 3A and 3B).
O 2 ⅐؊ Production in Diastolic Dysfunction Could Be Suppressed by NOS Inhibitors
Hypertension is known to cause increased oxidative stress in the vasculature, in part as a result of O 2 ⅐Ϫ production from uncoupled NOS. 6 Both endothelial NOS and nNOS have been reported in heart. 10, 27 To examine whether uncoupled NOS en- zymes were contributing to cardiac O 2 ⅐Ϫ production in hypertensive mice, LV tissue was incubated with the nonselective NOS inhibitor, L-NAME, or the selective nNOS inhibitor, 7N. 18 The percent reduction in O 2 ⅐Ϫ production between control and hypertensive animals was 65Ϯ22% for L-NAME-treated tissue and 100Ϯ34% for 7N-treated tissue (PϭNS), suggesting that nNOS uncoupling was responsible for most of the increase in O 2 ⅐Ϫ production in hypertensive mice ( Figure 3C ).
Cardiac Oxidation Was Associated With Less Cardiac BH 4 and Reduced NO
BH 4 is an essential cofactor for NOS. 28 When BH 4 is oxidized, NOS becomes uncoupled. 6, 10 Cardiac biopterins were quantified in LV tissue obtained on postoperative day 14. Consistent with the increase in O 2 ⅐Ϫ and evidence of NOS uncoupling, oxidized pterins were increased in hypertensive mice compared with controls (0.97Ϯ0.1 versus 0.46Ϯ0.3 pmol/mg protein; Pϭ0.04). Total biopterins (1.8Ϯ0.2 versus 1.9Ϯ0.3 pmol/mg protein) and reduced BH 4 (1.4Ϯ0.2 versus 0.94Ϯ0.2 pmol/mg protein) were unchanged between groups (PϭNS). Therefore, the ratio of reduced BH 4 to oxidized pterins, which reflects the amount of BH 4 available for NOS, was significantly lower in hypertensive mice compared with controls (1.2Ϯ0.4 versus 5.0Ϯ1.2; Pϭ0.02). Feeding BH 4 to DOCA-salt mice (nϭ3; days 1 to 14) increased cardiac BH 4 and total biopterins (PϽ0.01 versus DOCA-salt and control mice), demonstrating that oral administration could deliver reduced BH 4 to the myocardium. A 3.3-fold increase in the ratio of reduced BH 4 to oxidized pterins was seen in BH 4 -fed DOCA-salt animals compared with hypertensive mice without BH 4 feeding (PϭNS; Figure 3D ). NO production by NOS was reduced to similar degrees in DOCA-salt and in L-NAME-treated control hearts compared with untreated controls (1.1Ϯ0.02 versus 1.0Ϯ0.03 versus1.3Ϯ0.03 counts per minute, respectively; Pϭ0.0005; Figure 3E ) without changes in NOS isoform levels (PϭNS; Figure IV of the online-only Data Supplement).
BH 4 Prevented or Reversed Diastolic Dysfunction in Hypertensive Mice
We examined whether BH 4 could prevent diastolic function in mice treated with DOCA-salt. BH 4 administration pre-vented the hypertension associated with DOCA-salt treatment ( Figure 4A ). Assessment of diastolic function by echocardiography showed preserved LV relaxation with BH 4 on the basis of all indexes ( Figures 4B through 4D) . BH 4 prevented the increase in LV end-diastolic pressure seen with hypertensive DOCA-salt mice (6.3Ϯ0.9 mm Hg; PϭNS versus controls). The slope of the EDPVR was significantly lower in ⅐Ϫ reduction between control and DOCA LV tissue treated with the nonselective NOS inhibitor, L-NAME, and the selective neuronal NOS inhibitor, 7N. D, BH 4 and oxidized biopterins are quantified with the differential oxidation method and high-performance liquid chromatography. The ratio of reduced BH 4 to oxidized pterins in the heart is lower in DOCA mice vs controls. Feeding BH 4 to hypertensive mice (days 1 to 14) increases the cardiac ratio of reduced BH 4 to oxidized pterins. E, Total NOS activity is reduced to a similar degree in DOCA and L-NAME-treated control hearts.
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BH 4 prevention mice compared with DOCA-salt mice and was statistically indistinguishable from controls ( Figures 4E  and 4F ). Measures of systolic function, including the end-systolic pressure-volume relation and its volume axis intercept, were statistically equivalent between groups, and arterial elastance was unchanged, suggesting that neither arterial nor systolic function alterations explained the prevention of diastolic dysfunction seen with BH 4 ( Table I of the online- only Data Supplement). Moreover, BH 4 did not affect heart rate. The mean heart rate was 550 to 576 bpm during noninvasive and invasive studies in all of the groups (PϭNS). BH 4 could also reverse diastolic dysfunction once established. Hypertensive DOCA-salt mice were treated on postoperative day 11, a time when all of the hypertensive mice had evidence of diastolic dysfunction, with a 12-to 14-day course of BH 4 . Mean systolic blood pressure (96Ϯ2 and 99Ϯ3 mm Hg in controls; PϭNS) and the invasively measured LV end-systolic pressure were normalized in BH 4treated mice. LV end-diastolic pressure did not increase compared with controls (6.2Ϯ0.9 mm Hg; PϭNS). Echocardiographic indexes of diastolic function in the BH 4 treatment group mirrored those observed in the BH 4 prevention group and controls ( Figures 4B through 4D) . The EDPVR was significantly improved in the BH 4 -treated mice compared with the DOCA mice ( Figures 4E and 4F) . Systolic function, arterial elastance, and heart rate were similar in BH 4 -treated mice compared with all other groups (Table I of the onlineonly Data Supplement). The lack of improvement in blood pressure or lusitropy after treatment of DOCA-salt mice with H 4 N, a free radical scavenger without NOS catalytic activity, implied that the effects were specific to BH 4 (Figures 4B  through 4D ). 6, 10 Because lower blood pressures were observed in BH 4treated mice, it was unclear whether the improvements observed in diastolic function were a result of reduced blood pressure or an improvement in NOS coupling. Hydralazine, an antihypertensive agent that lowers blood pressure without recoupling NOS, was used to evaluate these possibilities. 29 Mice treated with hydralazine had a reduction in blood pressure similar to that observed with BH 4 . Nevertheless, diastolic dysfunction did not improve in hydralazine-treated mice, suggesting that the effect of BH 4 on DOCA-salt mice was independent of blood pressure lowering ( Figures 4A  through 4D) .
A Possible Mechanism for the BH 4 Effect
To determine whether abnormalities in diastolic function or the beneficial lusitropic effects seen with BH 4 in hypertensive mice were mediated at the myocyte level, cell shortening was measured in isolated myocytes. Cell length and fractional shortening were similar between groups (PϭNS; Table, and Figure III of the online-only Data Supplement), but the relaxation constant () was prolonged in myocytes from hypertensive hearts compared with controls (137.3Ϯ8.5 versus 79.3Ϯ4.9 ms; PϽ0.0001; Figure 4G ). Incubating myocytes from hypertensive mice with 10 mol/L BH 4 for 15 minutes normalized (86.0Ϯ7.6 ms; PϭNS versus control and PϽ0.0001 versus DOCA; Figure 4H ). The addition of BH 4 to control myocytes had no effect on or fractional shortening (PϭNS; Figure 4G , and Figure III Recently, nNOS-mediated oxidation changes in the phosphorylation state of phospholamban, a key protein controlling sarcoplasmic reticulum Ca 2ϩ pump activity and cytosolic Ca 2ϩ levels, have been described. 30, 31 The ratio of phosphorylated phospholamban to total phospholamban was quantified in DOCA-salt, control, BH 4 prevention, and BH 4 treatment groups ( Figure 4H ). DOCA-salt mice had a marked reduction in the ratio of phosphorylated phospholamban to total phospholamban compared with all of the other groups (0.09Ϯ0.04 versus 0.76Ϯ0.2 versus 1.2Ϯ0.1 versus 1.0Ϯ0.2, respectively; Pϭ0.003). Feeding BH 4 to control mice had no effect on the ratio of phosphorylated phospholamban to total phospholamban ( Figure VII of the online-only Data Supplement).
Cardiac Oxidation and Diastolic Dysfunction in ACE 1/8 Mice
We investigated the role of cardiac oxidation in the pathogenesis of diastolic dysfunction using ACE 1/8 mice. Because these mice express ACE only in the heart, their blood pressure is unchanged from controls. Moreover, these mice have normal systolic function. 11 Because cardiac angiotensin II levels are increased in ACE 1/8 mice and angiotensin II causes increased oxidative stress, we evaluated whether cardiac oxidation in the absence of hypertension resulted in diastolic dysfunction. 32, 33 Ten-week-old ACE 1/8 mice showed multiple indexes of diastolic dysfunction compared with controls ( Figures 5A through 5C ). O 2 ⅐Ϫ levels were higher in ACE 1/8 mice compared with control littermates (0.24Ϯ0.03 versus 0.14Ϯ0.3 mol ⅐ L Ϫ1 ⅐ mg Ϫ1 tissue; Pϭ0.04; Figure 5D ). O 2 ⅐Ϫ production was suppressed by 60Ϯ17% in ACE 1/8 mice by L-NAME. NOS inhibition had no effect on O 2 ⅐Ϫ production in control littermates, suggesting that uncoupled NOS was involved in the cardiac oxidation seen in ACE 1/8 mice ( Figure 5E ).
Discussion
Heart failure with preserved systolic function is growing in prevalence and has no specific therapies. 1, 2 One of the most common associated risk factors for diastolic dysfunction is hypertension. 4, 34 Here, we showed that mild hypertension resulted in diastolic dysfunction. This relaxation defect was associated with cardiac oxidation and reduced NOS NO production. NOS inhibitors suggested that the oxidative stress was in large part the result of uncoupled NOS. The increase in oxidized cardiac pterins and the concomitant decrease in reduced cardiac BH 4 further suggested uncoupled NOS. Prevention or reversal of diastolic dysfunction by BH 4 , but not HN 4 , treatment implied that NOS uncoupling played a pathogenic role in the diastolic changes observed. The impaired relaxation observed in isolated myocytes from hypertensive animals, coupled with the beneficial lusitropic effect observed by short-term treatment of these cells with BH 4 , supports the role of myocyte-specific uncoupled NOS as a mediator of diastolic dysfunction. Therefore, it appears that hypertension can cause diastolic dysfunction by oxidizing cardiac BH 4 , leading to myocyte-uncoupled NOS.
Our results are consistent with those of Takimoto et al 10 and Moens et al. 35 These investigators showed that transaortic constriction with resultant systolic dysfunction was associated with cardiac BH 4 depletion and NOS uncoupling. Exogenous BH 4 treatment halted the progression of ventricular remodeling, reversed fibrosis, and improved calcium handling in this model. In our case, the lusitropic role for NOS was suggested in the absence of systolic dysfunction, marked ventricular remodeling, or increased arterial elastance.
Inhibitor experiments showed that nNOS was the largest contributor to cardiac O 2 ⅐Ϫ production in diastolic dysfunction. The endothelial NOS and nNOS isoforms are known to be present in heart, and BH 4 depletion appears to result in uncoupling of either form. 7, 10, 36, 37 A growing body of work points to nNOS as an important modulator of cardiac nitrosoredox balance and function. 38 -41 For example, Zhang and coworkers 31 have shown that nNOS modulates cardiac relax-ation via effects on phospholamban phosphorylation. Interpretation that nNOS generates most of the increased oxidative stress in hypertensive mice may be misleading, however, if 7N is less specific than reported. 18 Our data suggest that reduced NO leads to phospholamban changes that are consistent with increased cytosolic Ca 2ϩ and diastolic dysfunction. The beneficial effects of BH 4 correlate with the phosphorylation state of phospholamban, consistent with work demonstrating that NO is a mediator of cardiac lusitropy and the finding that Ca 2ϩ handling and the phosphorylation state of phospholamban are subject to oxidative regulation. 7, 30, 31, 35, 42 Other possible targets of oxidative modification that were not examined in the present study include the sarcoplasmic reticulum Ca 2ϩ release channel, sarcoplasmic reticulum Ca 2ϩ pump, or the sarcolemmal L-type Ca 2ϩ channel. The troponin T-I79N mutation leads to diastolic dysfunction as a result of enhanced calcium myofilament sensitivity, 43 suggesting that oxidative stress-dependent changes in myofilament Ca 2ϩ sensitivity may be another possible mechanism.
Previously, it has been difficult to resolve the contributions of changes in the vasculature versus changes in the myocardium in the pathogenesis of diastolic dysfunction. 44 We attempted to address this quandary with isolated myocyte experiments and gene-targeted animals. The abnormal relaxation pattern observed in cardiomyocytes isolated from hypertensive mice, combined with the ability of BH 4 to normal-ize relaxation in these cells, supports the concept that diastolic dysfunction in this model is in large measure myocyte dependent. The ability of the renin-angiotensin system to lead to vascular oxidation and uncoupling of NOS is well documented. 6 Using a gene-targeted mouse that overexpressed ACE in the heart while simultaneously eliminating ACE elsewhere, we created a mouse that has increased cardiac oxidation and diastolic dysfunction in the absence of hypertension, suggesting that cardiac oxidation is sufficient to cause diastolic dysfunction. This notion is further supported by the lack of change in vascular elastance in the mildly hypertensive mice with diastolic dysfunction.
Because there is debate about the proper methodology to assess diastolic dysfunction, we chose to use both noninvasive and invasive means. 25, 45 Diastolic function was assessed with the combination of 3 echocardiographic modalities. 46 Two of these modalities, tissue Doppler imaging and color M-mode assessment of Vp, are relatively independent of cardiac loading conditions. 21, 47 Moreover, the invasively derived EDPVR, generally thought to be the standard for lusitropic assessment, was used. 25 The strong correlation observed between EЈ, Vp, and E/EЈ and the invasively derived EDPVR suggests that these techniques assess similar myocardial properties. Measures indicated perturbations in active and passive stiffness. The abnormal phosphorylation state of phospholamban observed in hypertensive mice would be expected to affect active relaxation predominantly. Be- Figure 5 . Cardiac-specific ACE overexpression results in increased oxidation and diastolic dysfunction. A through C, ACE 1/8 mice have reduced EЈ, lower Vp, and an increased E/EЈ ratio vs wild-type (wt) controls. D, Mean 2HO-ET levels are significantly higher in ACE 1/8 mice vs controls. E, L-NAME suppresses O 2 ⅐Ϫ production in ACE 1/8 mice (Pϭ0.004).
cause increased collagen deposition and hypertrophy were not observed, the increased passive stiffness may have resulted from enhanced myofilament Ca 2ϩ sensitivity, changes in titin isoform expression, or changes in the composition of collagen.
Oral BH 4 , but not HN 4 , was able to raise cardiac BH 4 levels and prevent or reverse the diastolic parameter changes seen in hypertensive mice. This suggests that the BH 4 effect was not the result of nonspecific radical scavenging. Nevertheless, BH 4 lowered blood pressure, in accordance with previously published data from human and animal studies, which may prevent or ameliorate diastolic dysfunction. 29, 48 Experiments with hydralazine, a direct vasodilator that does not recouple NOS, suggest otherwise. 29 In this case, hydralazine lowered blood pressure as much as BH 4 but did not prevent diastolic dysfunction.
Conclusions
This study demonstrates that cardiac oxidation can lead to BH 4 depletion, NOS uncoupling, and diastolic dysfunction. This dysfunction can be ameliorated by BH 4 treatment. Diastolic dysfunction can occur in the absence of changes in the vasculature. Finally, these results suggest that BH 4 may be of value in the treatment of diastolic dysfunction.
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